These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30595625)

  • 1. EU Clinical Trials Regulation 2014: Fetter or facilitator?
    Cave E
    Med Law Int; 2018 Jun; 18(2-3):179-194. PubMed ID: 30595625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REACHing for divergence?-UK chemical regulation post-Brexit.
    Jones LB; Burns CJ
    Integr Environ Assess Manag; 2024 Sep; 20(5):1529-1538. PubMed ID: 38712803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparedness and management of global public health threats at points of entry in Ireland and the EU in the context of a potential Brexit.
    Boland M; O'Riordan M
    Global Health; 2019 Sep; 15(1):53. PubMed ID: 31481126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does Brexit mean for UK tobacco control?
    Branston JR; Arnott D; Gallagher AWA
    Int J Drug Policy; 2021 Jun; 92():103044. PubMed ID: 33279366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do we make sense of chaos? Navigating health research regulation through the liminality of the Brexit process.
    Laurie G
    Med Law Int; 2018 Jun; 18(2-3):110-134. PubMed ID: 30595624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engaging with change: Information and communication technology professionals' perspectives on change at the mid-point in the UK/EU Brexit process.
    Lomas E; McLeod J
    PLoS One; 2020; 15(1):e0227089. PubMed ID: 31905215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How will Brexit affect health services in the UK? An updated evaluation.
    Fahy N; Hervey T; Greer S; Jarman H; Stuckler D; Galsworthy M; McKee M
    Lancet; 2019 Mar; 393(10174):949-958. PubMed ID: 30819519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexit and Animal Welfare Impact Assessment: Analysis of the Opportunities Brexit Presents for Animal Protection in the UK, EU, and Internationally.
    P McCulloch S
    Animals (Basel); 2019 Oct; 9(11):. PubMed ID: 31661920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexit and Animal Protection: Legal and Political Context and a Framework to Assess Impacts on Animal Welfare.
    McCulloch SP
    Animals (Basel); 2018 Nov; 8(11):. PubMed ID: 30453693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How will Brexit affect health and health services in the UK? Evaluating three possible scenarios.
    Fahy N; Hervey T; Greer S; Jarman H; Stuckler D; Galsworthy M; McKee M
    Lancet; 2017 Nov; 390(10107):2110-2118. PubMed ID: 28965715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not quite anyone's guess: Brexit, forensic science and legal medicine.
    Wilson TJ
    J Forensic Leg Med; 2019 Feb; 61():73-74. PubMed ID: 30471484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexit and Animal Welfare Impact Assessment: Analysis of the Threats Brexit Poses to Animal Protection in the UK, EU and Internationally.
    McCulloch SP
    Animals (Basel); 2019 Mar; 9(3):. PubMed ID: 30917541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Brexit on UK and EU Drug Regulation and Patient Access.
    Breckenridge A; Feldschreiber P
    Clin Pharmacol Ther; 2019 Apr; 105(4):923-925. PubMed ID: 30346627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights.
    Hofer MP; Criscuolo P; Shah N; Ter Wal ALJ; Barlow J
    Front Med (Lausanne); 2022; 9():1011082. PubMed ID: 36590956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
    Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
    Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.